Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are pr...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Vol. 23; no. 2; pp. 139 - 142
Main Authors: Ning, Yang‐Min, Maher, V. Ellen, Beaver, Julia A., Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Format: Journal Article
Language:English
Published: United States AlphaMed Press 01-02-2018
Subjects:
Health Services Accessibility
Humans
Immunotherapy
Prognosis
Urologic Neoplasms - immunology
Urologic Neoplasms - therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.
AbstractList Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.
Author Beaver, Julia A.
Pazdur, Richard
Ning, Yang‐Min
Blumenthal, Gideon M.
Goldberg, Kirsten B.
Maher, V. Ellen
Author_xml – sequence: 1
  givenname: Yang‐Min
  surname: Ning
  fullname: Ning, Yang‐Min
  email: ningy@cder.fda.gov
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
– sequence: 2
  givenname: V. Ellen
  surname: Maher
  fullname: Maher, V. Ellen
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
– sequence: 3
  givenname: Julia A.
  surname: Beaver
  fullname: Beaver, Julia A.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
– sequence: 4
  givenname: Kirsten B.
  surname: Goldberg
  fullname: Goldberg, Kirsten B.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
– sequence: 5
  givenname: Gideon M.
  surname: Blumenthal
  fullname: Blumenthal, Gideon M.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
– sequence: 6
  givenname: Richard
  surname: Pazdur
  fullname: Pazdur, Richard
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29180460$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v3CAQhlGVKt9_ofWxF6eAwYZLpdUqTSJF2Usj5YbGeHZDhWEL3kT774uVNG1uPc1oPt6B9zkhByEGJOQzoxesbcTX6RFjsNHHjcvTBaesq6lg8gM5ZlLoWmj6cFByqpq6Y1IfkZOcf1Ja0oYfkiOumaKipcfkbmEtekwwubCpLiH5fTWXcq6mWN2M4y7EcizB1mGu1jFVi-EJgsWhuk9zxzvw1RKSdSGOcEY-rsFnPH-Np-T---WP5XV9u7q6WS5uays6rmrLKXAuBWO8Ew3FTvFBougtDEIplKpH2vcM20bBWnDBFG_pAD0IwSgWB07Jtxfd7a4fcbAYpgTebJMbIe1NBGfed4J7NJv4ZKRiTSdZEfjyKpDirx3myYwuFyc8BIy7bJhutW6E1rKMdi-jNsWcE67fzjBqZhrmHQ0z0zAzjbL56d9Xvu39sf_vN56dx_3_6prV3XLFeFPo_gaCK6HT
CitedBy_id crossref_primary_10_1007_s11864_019_0637_2
crossref_primary_10_1097_PAS_0000000000001453
crossref_primary_10_1002_cpt_1123
crossref_primary_10_1634_theoncologist_2018_0084
Cites_doi 10.1634/theoncologist.2017-0087
10.3322/caac.21332
10.1200/JCO.2015.65.0218
10.1200/JCO.2011.34.8433
10.1016/j.clgc.2013.11.016
10.1200/JCO.2008.20.5534
10.1200/JCO.2011.37.7002
10.1016/j.clgc.2016.05.003
10.1093/jnci/djr062
ContentType Journal Article
Copyright Published 2017. This article is a U.S. Government work and is in the public domain in the USA
Copyright_xml – notice: Published 2017. This article is a U.S. Government work and is in the public domain in the USA
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1634/theoncologist.2017-0415
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

CrossRef
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-490X
EndPage 142
ExternalDocumentID 10_1634_theoncologist_2017_0415
29180460
ONCO12308
Genre editorial
Editorial
Commentary
GroupedDBID ---
0R~
123
18M
1OC
24P
2WC
36B
4.4
53G
5VS
AAPXW
AAVAP
AAWTL
AAZKR
ABPTD
ABXVV
ACXQS
ADBBV
ADXAS
AEGXH
AENEX
AJAOE
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BFHJK
CS3
DCZOG
DIK
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
F5P
FRP
GROUPED_DOAJ
GX1
H13
HYE
HZ~
IAO
IHR
INH
LUTES
LYRES
O9-
OK1
P2P
P2W
RAO
RHF
RHI
ROL
ROX
RPM
SUPJJ
SV3
TOX
TR2
UDS
W2D
W8F
WIN
WOHZO
WOQ
WOW
XSB
ZZTAW
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
ABEJV
CITATION
7X8
5PM
ID FETCH-LOGICAL-c4728-c20a22541127430e782d5e4bcad488e58be0bb1e638af42418260daba4410e163
IEDL.DBID RPM
ISSN 1083-7159
IngestDate Tue Sep 17 21:18:00 EDT 2024
Fri Aug 16 22:10:26 EDT 2024
Thu Nov 21 21:53:33 EST 2024
Wed Oct 16 00:49:20 EDT 2024
Sat Aug 24 01:12:24 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4728-c20a22541127430e782d5e4bcad488e58be0bb1e638af42418260daba4410e163
Notes .
Disclosures of potential conflicts of interest may be found at the end of this article
SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
Disclosures of potential conflicts of interest may be found at the end of this article.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/
PMID 29180460
PQID 1969934995
PQPubID 23479
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5813751
proquest_miscellaneous_1969934995
crossref_primary_10_1634_theoncologist_2017_0415
pubmed_primary_29180460
wiley_primary_10_1634_theoncologist_2017_0415_ONCO12308
PublicationCentury 2000
PublicationDate February 2018
PublicationDateYYYYMMDD 2018-02-01
PublicationDate_xml – month: 02
  year: 2018
  text: February 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The oncologist (Dayton, Ohio)
PublicationTitleAlternate Oncologist
PublicationYear 2018
Publisher AlphaMed Press
Publisher_xml – name: AlphaMed Press
References 2011; 103
2017
2011; 29
2016; 15
2017; 22
2009; 27
2014; 12
30
2012; 30
2016; 34
2016; 66
Santis (2021122509424523500_onco12308-bib-0008); 30
Sonpavde (2021122509424523500_onco12308-bib-0007) 2014; 12
Bellmunt (2021122509424523500_onco12308-bib-0003) 2009; 27
Necchi (2021122509424523500_onco12308-bib-0009) 2016; 15
U.S. Food and Drug Administration (2021122509424523500_onco12308-bib-0010)
U.S. Food and Drug Administration (2021122509424523500_onco12308-bib-0011) 2017
Ning (2021122509424523500_onco12308-bib-0001) 2017; 22
U.S. Food and Drug Administration (2021122509424523500_onco12308-bib-0013)
Siegel (2021122509424523500_onco12308-bib-0002) 2016; 66
Johnson (2021122509424523500_onco12308-bib-0012) 2011; 103
Galsky (2021122509424523500_onco12308-bib-0006) 2011; 29
Petrylak (2021122509424523500_onco12308-bib-0005) 2016; 34
Choueiri (2021122509424523500_onco12308-bib-0004) 2012; 30
References_xml – volume: 15
  start-page: 23
  year: 2016
  end-page: 30
  article-title: Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first‐line setting of metastatic urothelial carcinoma: A systematic review and meta‐analysis
  publication-title: Clin Genitourin Cancer
– volume: 66
  start-page: 7
  year: 2016
  end-page: 30
  article-title: Cancer Statistics, 2016
  publication-title: CA Cancer J Clin
– volume: 34
  start-page: 1500
  year: 2016
  end-page: 1509
  article-title: Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second‐line treatment for locally advanced or metastatic urothelial carcinoma: An open‐label, three‐arm, randomized controlled phase II trial
  publication-title: J Clin Oncol
– volume: 103
  start-page: 636
  year: 2011
  end-page: 644
  article-title: Accelerated approval of oncology products: The Food and Drug Administration experience
  publication-title: J Natl Cancer Inst
– volume: 12
  start-page: 71
  year: 2014
  end-page: 73
  article-title: Cisplatin‐ineligible and chemotherapy‐ineligible patients should be the focus of new drug development in patients with advanced bladder cancer
  publication-title: Clin Genitourin Cancer
– year: 2017
– volume: 27
  start-page: 4454
  year: 2009
  end-page: 4461
  article-title: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum‐containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
  publication-title: J Clin Oncol
– volume: 30
  start-page: 507
  year: 2012
  end-page: 512
  article-title: Double‐blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum‐pretreated metastatic urothelial cancer
  publication-title: J Clin Oncol
– volume: 29
  start-page: 2432
  year: 2011
  end-page: 2438
  article-title: Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin‐based chemotherapy
  publication-title: J Clin Oncol
– volume: 22
  start-page: 743
  year: 2017
  end-page: 749
  article-title: FDA Approval Summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum‐containing chemotherapy
  publication-title: The Oncologist
– volume: 30
  start-page: 191
  end-page: 199
  article-title: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin‐based chemotherapy: EORTC study 30986
  publication-title: J Clin Oncol 2011;
– volume: 22
  start-page: 743
  year: 2017
  ident: 2021122509424523500_onco12308-bib-0001
  article-title: FDA Approval Summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy
  publication-title: The Oncologist
  doi: 10.1634/theoncologist.2017-0087
  contributor:
    fullname: Ning
– volume: 66
  start-page: 7
  year: 2016
  ident: 2021122509424523500_onco12308-bib-0002
  article-title: Cancer Statistics, 2016
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21332
  contributor:
    fullname: Siegel
– ident: 2021122509424523500_onco12308-bib-0010
  contributor:
    fullname: U.S. Food and Drug Administration
– volume: 34
  start-page: 1500
  year: 2016
  ident: 2021122509424523500_onco12308-bib-0005
  article-title: Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three-arm, randomized controlled phase II trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.65.0218
  contributor:
    fullname: Petrylak
– volume: 29
  start-page: 2432
  year: 2011
  ident: 2021122509424523500_onco12308-bib-0006
  article-title: Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.34.8433
  contributor:
    fullname: Galsky
– volume: 12
  start-page: 71
  year: 2014
  ident: 2021122509424523500_onco12308-bib-0007
  article-title: Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2013.11.016
  contributor:
    fullname: Sonpavde
– volume: 27
  start-page: 4454
  year: 2009
  ident: 2021122509424523500_onco12308-bib-0003
  article-title: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.5534
  contributor:
    fullname: Bellmunt
– year: 2017
  ident: 2021122509424523500_onco12308-bib-0011
  contributor:
    fullname: U.S. Food and Drug Administration
– volume: 30
  start-page: 191
  ident: 2021122509424523500_onco12308-bib-0008
  article-title: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
  publication-title: J Clin Oncol 2011;
  contributor:
    fullname: Santis
– volume: 30
  start-page: 507
  year: 2012
  ident: 2021122509424523500_onco12308-bib-0004
  article-title: Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.7002
  contributor:
    fullname: Choueiri
– volume: 15
  start-page: 23
  year: 2016
  ident: 2021122509424523500_onco12308-bib-0009
  article-title: Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: A systematic review and meta-analysis
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2016.05.003
  contributor:
    fullname: Necchi
– ident: 2021122509424523500_onco12308-bib-0013
  contributor:
    fullname: U.S. Food and Drug Administration
– volume: 103
  start-page: 636
  year: 2011
  ident: 2021122509424523500_onco12308-bib-0012
  article-title: Accelerated approval of oncology products: The Food and Drug Administration experience
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr062
  contributor:
    fullname: Johnson
SSID ssj0015932
Score 2.3041537
Snippet Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 139
SubjectTerms Health Services Accessibility
Humans
Immunotherapy
Prognosis
Urologic Neoplasms - immunology
Urologic Neoplasms - therapy
Title Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2017-0415
https://www.ncbi.nlm.nih.gov/pubmed/29180460
https://search.proquest.com/docview/1969934995
https://pubmed.ncbi.nlm.nih.gov/PMC5813751
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NSwMxEA22B_Eifls_SgSvabPdTZMcS21RxCpowduS7KYqtGmp9v87k90tFi_icUk2u7xMmDfMzAsh1zpRTmXKsEmuuiwxWjAlpGYdE3WMziMpOfYO3z7L0au6GaBMjqh6YULRfmY_Wn46a_mP91BbuZhl7apOrP300BcqiqWI2jVSA25Yhehl6kDouEhxqphJeCqLurpx0sbeQB_EoAFCLOuSDDvUURBYRwpThJve6Rfl_F05-ZPRBpc03CO7JZekveKf98mW8wdk-6HMlh-SUS_LwKvgHvs3GqSMaS9ckEi_5vQOO0PK_isIlymwV9orKwLoeIkjUzBO2sfbhvx8Zo7IeDh46d-y8v4EliWyo1jW4QaOawKUCngCd0AGcuESm5kcjq0TyjpubeTgCJpJAq4cQg2eG2uAInEHiB2Tup97d0pooo3tytgqMUEOaK02ykihUT1PWsMbhFe4pYtCJiPF8AJQTzdQTxH1FFFvkKsK3xRMGvMUxrv56jNFxR4dQygGc04KvNeLVhvVIHJjJ9YTUC57cwSsKMhml1YDb4Y9--t_po-j_iP4d67O_v3Nc7ID66mi2vuC1L-WK3dJap_5qgk0_u6-GUz4G8E99Io
link.rule.ids 230,315,729,782,786,887,27934,27935,53802,53804
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NTxsxEB0BlUovpbS0TemHkXo18X44to9RAAVBAhIg9WbZuw5FIg4C8v87491FRFwqjivvp9-O_Ebz5hngtyl10JV2fFbrAS-dkVxLZXjustyZOlNKUO_w-EJN_-iDQ7LJkV0vTBLtV_5mP97O9-PN36StvJtX_U4n1j-fjKTOCiWz_jq8wXgVeZekt8UDaYqmyKkLrvColXUNirJP3YEx2UHjJJKwS3HqUSdLYJNpKhKurk8vSOdL7eRzTpsWpaOtV37OB3jfslA2bIa3YS3Ej_B20tbZP8F0WFW4HtHfEa9ZMkFmw7S1IntcsGPqKWk7tzDRZsh72bDVErCrexq5xd-ajWiforiYux24Ojq8HI15u_MCr0qVa17lwmGgl0jGkGGIgDSilqH0lasx4IPUPgjvs4DB62YlkgBMUkTtvENyJQLO9GfYiIsYvgIrjfMDVXgtZ8QevTdOOyUN-e4p70QPRDff9q4x2LCUmCBadgUtS2hZQqsHex0uFoOBKhwuhsXywZLXjykwicNzvjQ4Pd20A7gHagXBpxPIaHt1BAFLhtstQHhlwvp_39OeTUdnyAyE_vbqZ_6CzfHl5NSeHk9PduEd3ls3mvHvsPF4vww_YP2hXv5MAfAPb08JKA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEB6aFEIvfT-cvlToVVmtV7Kko3FiEto4gTbQm5B25TQQyyaJ_39mtLumJpfSHhdpX_o06Btm5huAr1aaaGrj-bwxIy69VdwobfnQl0Nvm1JrQbXDxz_07Jc5PCKZnE2rr5y0X4erg3S9OEhXv3Nu5WpRF32eWHF-OlGmrLQqi1UzL3bgMdqskL2j3gUQlK3aQKepuMarLrVrVMmCKgRTloTGhaTkLs2pTp1kgW1pKFC4fUY9IJ4P8yf_5LX5YJo--49feg5POzbKxu2UF_Aoppewd9rF21_BbFzXeC7RLkmXLIshs3FuscjuluyEaku6Ci50uBnyXzbucgrYxQ2NXOP2ZhPqV5SWC_8aLqZHPyfHvOvAwGuph4bXQ-HR4CWSMmQaIiKdaFSUofYNGn5UJkQRQhnRiP1cIhlAZ0U0PngkWSLiar-B3bRM8R0waX0Y6SoYNScWGYL1xmtlSX9PBy8GIPo1d6tWaMORg4KIuS3EHCHmCLEBfOmxcWgUFOnwKS7Xt440f2yFzhzOedtitXloD_IA9BaKmwkkuL09gqBl4e0OJLwz4_233-nOZpMzZAjC7P_zOz_D3vnh1H0_mX17D0_w0aZNHf8Au3c36_gRdm6b9adsA_fOzguo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Accelerating+Early+Access+to+Immunotherapies+for+Advanced+Urothelial+Carcinoma&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Ning%2C+Yang%E2%80%90Min&rft.au=Maher%2C+V.+Ellen&rft.au=Beaver%2C+Julia+A.&rft.au=Goldberg%2C+Kirsten+B.&rft.date=2018-02-01&rft.issn=1083-7159&rft.eissn=1549-490X&rft.volume=23&rft.issue=2&rft.spage=139&rft.epage=142&rft_id=info:doi/10.1634%2Ftheoncologist.2017-0415&rft.externalDBID=10.1634%252Ftheoncologist.2017-0415&rft.externalDocID=ONCO12308
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon